WALTER E. STAMM, M.D.; GEORGE W. COUNTS, M.D.; KENNETH F. WAGNER, D.O.; DAVID MARTIN, M.D.; DAVID GREGORY, M.D.; MARY McKEVITT, R.N.; MARVIN TURCK, M.D.; KING K. HOLMES, M.D., Ph.D.
To study once-daily antimicrobial prophylaxis of urinary tract infections, we gave trimethoprim-sulfamethoxazole (40 mg/200 mg), trimethoprim (100 mg), nitrofurantoin macrocrystals (100 mg); or placebo to 60 women for 6 months. During prophylaxis, infections per patient year were comparable in the groups receiving trimethoprim (0.0), nitrofurantoin (0.14), or trimethoprim-sulfamethoxazole (0.15) and occurred less frequently than in patients receiving placebo (2.8; P < 0.001, placebo versus each drug regimen). The effectiveness of prophylaxis was limited to the 6 months that antimicrobials were given, and infections were more likely to develop after prophylaxis in women who had three or more infections in the year before prophylaxis (P < 0.005). Further, women whose preprophylaxis infection was positive for antibody-coated bacteria were more likely to have same-strain relapse when infections recurred (P = 0.001). Emergence of trimethoprim-resistant Escherichia coli was rare, but non-E. coli infections occurred more often after prophylaxis (P < 0.05). Prophylaxis with these drugs is effective, well tolerated, and did not produce emergence of resistant E. coli but may predispose to non-E. coli urinary tract infections after its discontinuation.
Learn more about subscription options.
Register Now for a free account.
STAMM WE, COUNTS GW, WAGNER KF, MARTIN D, GREGORY D, McKEVITT M, et al. Antimicrobial Prophylaxis of Recurrent Urinary Tract Infections: A Double-Blind, Placebo-Controlled Trial. Ann Intern Med. 1980;92:770-775. doi: 10.7326/0003-4819-92-6-770
Download citation file:
Published: Ann Intern Med. 1980;92(6):770-775.
Infectious Disease, Nephrology, Urinary Tract Infection, Urological Disorders.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only